Arabic Arabic English English French French German German
dark

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

– Collaboration Will Leverage Lantern’s RADR® A.I. Platform to Accelerate Development of Actuate’s Drug Candidate, 9-ING-41
– Actuate’s 9-ING-41 is a Best-In-Class Drug Candidate for Cancer & Fibrotic Diseases
– Lantern Will Receive Equity Based on Meeting Development Milestones & May Receive Additional Equity Based on Use of Findings in Future Development Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

The Seven Stages of Alzheimer’s Disease Explained

Next Post

OneOncology Appoints Two New Board Members

Related Posts
Total
0
Share